Cooperative Agreement UG3DA063344
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$685K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10017, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $1,585,991 study to evaluate the efficacy of combining transcranial direct current stimulation (tDCS) with cognitive reappraisal training to reduce craving and reactivity to drug cues in individuals with cocaine use disorder. The study, being conducted at the Icahn School of Medicine at Mount Sinai, will perform a double-blind...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $197,640 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a pilot randomized controlled trial of a digital therapeutic called AMP-C. The goal of AMP-C is to address the co-occurring conditions of cannabis use disorder (CUD) and major depressive disorder (MDD) by targeting reward dysfunction, a...
This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $280,207 to Mobile Health Interventions LLC to develop a digital intervention called the Adolescent CLEAR30 to reduce cannabis use among youth aged 13-17. The proposed intervention will include personalized feedback, daily communications, guided meditations, resource pages, multimedia content, optional human support, and an AI-driven...
This $311,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and pilot test a mobile-enhanced, web-based intervention for reducing cannabis use among non-college young adults (YAs) engaging in frequent or high-intensity cannabis use. The key products and services to be delivered through this 3-year project include: 1) Development of the "TAKE 5" intervention using focus groups...
This Project Grant award of $816,604 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to determine the extent to which specific neurological markers moderate responses to repetitive transcranial magnetic stimulation (rTMS) treatments for substance use disorders (SUDs). The research aims to personalize rTMS interventions by identifying neuromarkers of dysregulated activity in the reward and cognitive control...
This $2,118,992 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a longitudinal study investigating the neural and psychiatric consequences of cannabis use in depressed adolescents. The research aims to prospectively examine the effects of cannabis, the most widely used illicit drug among teenagers, on reward and pain neurocircuits in adolescents with depression. The study will evaluate 250...
This Project Grant award of $674,709 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Missouri System. The grant aims to conduct a crossover study to examine the neurocircuitry and neurobiological mechanisms mediating the effects of continuous theta burst stimulation (cTBS) applied to the right inferior frontal gyrus (R.IFG) and the dorsomedial prefrontal cortex (preSMA) on inhibitory control and...